Download Files:
Products Details
Product Description
– Anizatrectinib (hTrkA-IN-1) is a potent and orally active inhibitor of TrkA kinase with an IC50 of 1.3 nM, compound 2 extracted from patent WO2015175788. Anizatrectinib can be used for the study of inflammatory disease, such as prostatitis, pelvic, et al[1].
Web ID
– HY-136535
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C29H32FN7O2
References
– [1]Shelley Allen, et al. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor. Patent WO2015175788A1.
CAS Number
– 1824664-89-2
Molecular Weight
– 529.61
SMILES
– O=C(NC1=C(C)C(C2=CN=C(C)N=C2)=NN1C3=CC=CC=C3)N[C@@H]4CN(CCOC)C[C@H]4C5=CC=CC(F)=C5
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– Trk Receptor
Isoform
– TrkA
Pathway
– Neuronal Signaling;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
